Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The record now presents details of the completed pembrolizumab trial for extensive-stage small cell lung cancer, including its treatment arms, eligibility criteria, outcomes, and study locations.
    Difference
    54%
    Check dated 2026-11-08T04:49:43.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The page no longer displays a 403 Forbidden message and instead shows the standard ClinicalTrials.gov interface, with the study content area appearing blank. The site revision label changes from v3.7.2 to v3.8.0.
    Difference
    0.6%
    Check dated 2026-11-01T02:15:59.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces transition updates and says federal agencies are using “Super Intelligence” instead of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T02:16:09.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-18T02:00:12.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The footer revision number changed from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T02:37:30.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page now loads a 403 Forbidden error instead of the expected study details, indicating access to the record is blocked. The visible content shows a 403 message and header HTML, replacing the usual study information and navigation.
    Difference
    18%
    Check dated 2026-09-20T01:06:15.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.